Summary:
- The article discusses a proposal by the Trump administration to change the way the FDA reviews new drug applications, potentially reducing the role of expert advisory committees.
- The proposed changes could speed up the drug approval process, but critics argue that it could also compromise the safety and effectiveness of new drugs by bypassing independent expert review.
- The article highlights concerns that the proposed changes are driven by industry interests rather than public health considerations, and could undermine the FDA's role in ensuring the safety and efficacy of new medications.